The transition to low-global-warmingpotential (low-GWP) propellants is one of the most significant changes to pressurised metered dose inhaler (pMDI) development...

The pharmaceutical respiratory inhalation sector is entering its second major propellant transition. In response to the Montreal Protocol requirements, the first...

The inhaled medicines pipeline is changing, expanding from conventional small molecules towards proteins, peptides, nucleic acids and other complex therapeutics....